EpiGenOnco, LLC is a biopharmaceutical company, headquartered in Philadelphia, dedicated to the discovery and development of new treatments for cancer based on reprogramming the epigenome…
WHAT WE DO
We screen for and validate a compounds’ potential epigenetic activity
We’ve identified a new molecule that inhibits CDK9 and modulates the epigenome
We study cellular and animal models of disease to identify and validate potential epigenetic targets.
We use these to understand the function of specific genes that encode epigenetic regulators
We advance leads into preclinical development & beyond in collaboration with 3rd party service providers
Our mission is to develop new treatments in the fight against cancer. We are tenaciously driven to discover and develop new drugs with a focus on reprogramming cancer cells by targeting an aberrant epigenome. In short, we aim to turn ground-breaking science into practical benefit to improve the lives of people around the world.